RedHill Biopharma Ltd. (RDHL) 10-Year Financial Performance & Capital Metrics

RDHL • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsGastrointestinal Therapeutics

AboutRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Show more

Revenue $8M +23.2%
EBITDA -$14M -195.7%
Net Income -$8M -134.6%
EPS (Diluted) -7.00 -115.2%
Gross Margin 60.31% +28.2%
EBITDA Margin -173.99% -177.7%
Operating Margin -181.69% -193.9%
Net Margin -102.8% -128.1%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -265.69 -871.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 1155.9%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.38%

5Y5.04%

3Y-54.57%

TTM157.62%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM69.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM90.7%

ROCE

10Y Avg-33.82%

5Y Avg9.65%

3Y Avg95.91%

Latest-

Peer Comparison

Gastrointestinal Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRWDIronwood Pharmaceuticals, Inc.	735.31M	4.52	821.82	-20.63%	8.42%		14.06%
TAKTakeda Pharmaceutical Company Limited	51.59B	16.33	0.49	7.45%	0.75%	0.46%	100%	0.73
RDHLRedHill Biopharma Ltd.	6.67M	1.31	-0.19	23.17%	-97.52%
EVOKEvoke Pharma, Inc.	18.95M	11.00	-3.91	97.84%	-36.23%	-155.44%		0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3K	101K	4.01M	8.36M	6.29M	64.36M	85.76M	61.8M	6.53M	8.04M
Revenue Growth %	-1%	32.67%	38.67%	1.09%	-0.25%	9.23%	0.33%	-0.28%	-0.89%	0.23%
Cost of Goods Sold+	22M	30.54M	2.13M	2.84M	2.26M	36.89M	49.41M	33.34M	3.46M	3.19M
COGS % of Revenue	7334%	302.41%	0.53%	0.34%	0.36%	0.57%	0.58%	0.54%	0.53%	0.4%
Gross Profit+	-22M	-30.44M	1.88M	5.52M	4.03M	27.47M	36.35M	28.46M	3.07M	4.85M
Gross Margin %	-7333%	-301.41%	0.47%	0.66%	0.64%	0.43%	0.42%	0.46%	0.47%	0.6%
Gross Profit Growth %	-4.69%	-0.38%	1.06%	1.94%	-0.27%	5.81%	0.32%	-0.22%	-0.89%	0.58%
Operating Expenses+	22M	30.64M	53.85M	44.85M	47.23M	91.15M	117.49M	71.31M	-9.56M	19.46M
OpEx % of Revenue	7335%	303.41%	13.44%	5.37%	7.51%	1.42%	1.37%	1.15%	-1.46%	2.42%
Selling, General & Admin	4.13M	5.4M	20.04M	19.99M	29.81M	74.66M	87.99M	64.03M	30.98M	15.52M
SG&A % of Revenue	1378%	53.5%	5%	2.39%	4.74%	1.16%	1.03%	1.04%	4.74%	1.93%
Research & Development	17.77M	25.24M	32.97M	24.86M	17.42M	16.49M	29.5M	7.28M	3.53M	1.59M
R&D % of Revenue	5923.67%	249.91%	8.23%	2.97%	2.77%	0.26%	0.34%	0.12%	0.54%	0.2%
Other Operating Expenses	100K	0	845K	0	0	0	0	0	-44.06M	2.36M
Operating Income+	-22M	-30.54M	-51.97M	-39.33M	-43.2M	-63.68M	-81.14M	-42.84M	12.63M	-14.61M
Operating Margin %	-7334%	-302.41%	-12.97%	-4.7%	-6.87%	-0.99%	-0.95%	-0.69%	1.93%	-1.82%
Operating Income Growth %	-1.07%	-0.39%	-0.7%	0.24%	-0.1%	-0.47%	-0.27%	0.47%	1.29%	-2.16%
EBITDA+	-21.97M	-30.5M	-51.89M	-39.24M	-41.99M	-54.94M	-62.99M	-34.69M	14.62M	-13.99M
EBITDA Margin %	-7322%	-301.97%	-12.95%	-4.69%	-6.67%	-0.85%	-0.73%	-0.56%	2.24%	-1.74%
EBITDA Growth %	-1.07%	-0.39%	-0.7%	0.24%	-0.07%	-0.31%	-0.15%	0.45%	1.42%	-1.96%
D&A (Non-Cash Add-back)	36K	44K	81K	90K	1.21M	8.74M	18.15M	8.15M	1.99M	619K
EBIT	-22M	-30.54M	-45.54M	-38.82M	-41.91M	-63.72M	-81.18M	-30.34M	24.28M	-8.21M
Net Interest Income+	224K	275K	220K	237K	5.02K	-12.27M	-16.58M	-41.19M	-273K	78K
Interest Income	236K	282K	6.5M	678K	444.43K	176K	51K	140K	94K	133K
Interest Expense	12K	7K	77K	167K	439.42K	12.45M	16.57M	41.33M	367K	55K
Other Income/Expense	812K	1.17M	6.43M	511K	897K	-12.49M	-16.61M	-28.82M	11.28M	6.34M
Pretax Income+	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Pretax Margin %	-7030%	-290.79%	-11.37%	-4.64%	-6.72%	-1.18%	-1.14%	-1.16%	3.66%	-1.03%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Net Margin %	-7030%	-290.79%	-11.37%	-4.64%	-6.72%	-1.18%	-1.14%	-1.16%	3.66%	-1.03%
Net Income Growth %	-0.97%	-0.39%	-0.55%	0.15%	-0.09%	-0.8%	-0.28%	0.27%	1.33%	-1.35%
Net Income (Continuing)	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-950.00	-1100.00	-1300.00	-850.00	-700.00	-1000.00	-1000.00	-600.00	46.00	-7.00
EPS Growth %	-0.58%	-0.16%	-0.18%	0.35%	0.18%	-0.43%	0%	0.4%	1.08%	-1.15%
EPS (Basic)	-950.00	-1100.00	-1300.00	-850.00	-700.00	-1000.00	-1000.00	-600.00	46.00	-7.00
Diluted Shares Outstanding	22.34K	25.76K	35.31K	46.24K	59.38K	72.85K	93.05K	123.86K	518.24K	2.46M
Basic Shares Outstanding	22.16K	25.7K	35.31K	46.24K	59.38K	72.85K	93.05K	123.86K	518.24K	2.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60.51M	67.81M	51.68M	56.79M	53.21M	70.5M	89.15M	85.9M	16.14M	11.91M
Cash & Short-Term Investments	58.14M	66.15M	46.2M	53.19M	47.87M	29.79M	38M	19.98M	6.36M	4.62M
Cash Only	21.52M	53.79M	16.45M	29M	29.02M	29.3M	29.47M	19.97M	5.57M	4.62M
Short-Term Investments	36.62M	12.37M	29.75M	24.18M	18.85M	498K	8.53M	15K	790.04K	0
Accounts Receivable	220K	492K	2.26M	1.4M	1.64M	29.29M	32.52M	37.88M	3.29M	3.57M
Days Sales Outstanding	26.77K	1.78K	206.05	60.91	94.86	166.11	138.43	223.7	183.62	161.83
Inventory	-34.47M	1.11M	653K	769K	1.88M	6.53M	14.81M	11.01M	4.39M	3.65M
Days Inventory Outstanding	-	13.31	112.11	98.94	304.09	64.57	109.41	120.54	463.14	417.49
Other Current Assets	0	0	0	0	0	0	0	16M	797.04K	0
Total Non-Current Assets+	6.32M	6.4M	5.67M	5.62M	20.89M	109.75M	92.04M	72.97M	6.91M	6.13M
Property, Plant & Equipment	124K	165K	230K	163K	3.81M	5.7M	4.22M	7.19M	1.18M	437K
Fixed Asset Turnover	0.02x	0.61x	17.42x	51.29x	1.65x	11.29x	20.31x	8.59x	5.52x	18.41x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	6.06M	6.09M	5.29M	5.32M	16.93M	87.88M	71.64M	65.63M	5.58M	5.55M
Long-Term Investments	134K	137K	152K	140K	152K	0	16.17M	150K	147K	148K
Other Non-Current Assets	134K	137K	152K	-5.62M	-20.73M	32.33M	16.17M	150K	41	0
Total Assets+	66.83M	74.21M	57.34M	62.41M	74.1M	180.24M	181.19M	158.87M	23.05M	18.04M
Asset Turnover	0.00x	0.00x	0.07x	0.13x	0.08x	0.36x	0.47x	0.39x	0.28x	0.45x
Asset Growth %	1.32%	0.11%	-0.23%	0.09%	0.19%	1.43%	0.01%	-0.12%	-0.85%	-0.22%
Total Current Liabilities+	5.51M	5.36M	11.83M	10.38M	10.62M	73.23M	81.47M	197.45M	19.24M	22.22M
Accounts Payable	119K	60K	4.8M	3.32M	4.18M	11.55M	11.66M	4.23M	3.28M	7.86M
Days Payables Outstanding	1.97	0.72	824.94	427.66	676.03	114.3	86.17	46.31	345.9	898.89
Short-Term Debt	0	0	0	0	0	1.71M	1.62M	115.22M	718K	353K
Deferred Revenue (Current)	0	0	0	0	1000K	1000K	1000K	0	0	0
Other Current Liabilities	325K	393K	1.06M	1.46M	-2.89M	-1.71M	12.03M	49.65M	10.76M	10.96M
Current Ratio	10.97x	12.66x	4.37x	5.47x	5.01x	0.96x	1.09x	0.44x	0.84x	0.54x
Quick Ratio	17.23x	12.45x	4.31x	5.40x	4.84x	0.87x	0.91x	0.38x	0.61x	0.37x
Cash Conversion Cycle	-	1.79K	-506.78	-267.81	-277.09	116.37	161.67	297.92	300.85	-319.58
Total Non-Current Liabilities+	1.24M	6.16M	448K	844K	3.48M	93.14M	90.84M	9.82M	1.74M	503K
Long-Term Debt	0	0	0	0	0	81.39M	83.62M	0	0	0
Capital Lease Obligations	0	0	0	0	2.98M	3.81M	2.57M	6.44M	455K	3K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.24M	6.16M	448K	844K	500K	7.95M	4.65M	3.37M	540K	500K
Total Liabilities	6.75M	11.51M	12.28M	11.22M	14.1M	166.38M	172.31M	207.27M	20.98M	22.73M
Total Debt+	0	0	0	0	3.81M	86.9M	87.81M	122.69M	1.17M	356K
Net Debt	-21.52M	-53.79M	-16.45M	-29M	-25.21M	57.61M	58.34M	102.72M	-4.4M	-4.26M
Debt / Equity	-	-	-	-	0.06x	6.27x	9.89x	-	0.57x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	0.08x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.30x	-
Interest Coverage	-1833.50x	-4363.29x	-674.96x	-235.51x	-98.31x	-5.12x	-4.90x	-1.04x	34.42x	-265.69x
Total Equity+	60.08M	62.7M	45.06M	51.19M	60M	13.86M	8.88M	-48.4M	2.07M	-4.68M
Equity Growth %	1.4%	0.04%	-0.28%	0.14%	0.17%	-0.77%	-0.36%	-6.45%	1.04%	-3.26%
Book Value per Share	2688.97	2434.05	1276.12	1106.96	1010.41	190.30	95.37	-390.77	3.99	-1.90
Total Shareholders' Equity	60.08M	62.7M	45.06M	51.19M	60M	13.86M	8.88M	-48.4M	2.07M	-4.68M
Common Stock	343K	441K	575K	767K	962K	1.05M	1.5M	2.83M	21.44M	35.04M
Retained Earnings	-61.94M	-89.64M	-132.94M	-169.09M	-208.36M	-280.33M	-367.87M	-433.86M	-407.74M	-414.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-126K	-170K	-251K	-341K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.83M	-28.26M	-44.77M	-34.46M	-40.75M	-48.58M	-65.05M	-29.18M	-35.82M	-9.37M
Operating CF Margin %	-5942%	-279.78%	-11.17%	-4.12%	-6.48%	-0.75%	-0.76%	-0.47%	-5.49%	-1.16%
Operating CF Growth %	-0.46%	-0.59%	-0.58%	0.23%	-0.18%	-0.19%	-0.34%	0.55%	-0.23%	0.74%
Net Income	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Depreciation & Amortization	36K	44K	81K	90K	1.21M	8.74M	18.15M	8.15M	1.99M	619K
Stock-Based Compensation	1.36M	1.68M	2.23M	2.68M	3.03M	4.2M	10.21M	5.67M	1.65M	665K
Deferred Taxes	-638K	-1.26M	-5.08M	136K	0	195K	123K	0	0	0
Other Non-Cash Items	-69K	94K	-123K	35K	-347K	6.03M	5.37M	20.65M	-47.79M	-4.44M
Working Capital Changes	2.57M	553K	3.66M	1.42M	-2.34M	8.42M	-1.15M	8.01M	-15.58M	2.05M
Change in Receivables	701.73K	713.24K	-1.43M	570K	-258K	-27.44M	-3.02M	-2.85M	33.43M	52K
Change in Inventory	0	0	-653K	-116K	-1.11M	-4.64M	-8.29M	3.8M	2.38M	738K
Change in Payables	1.87M	-158K	4.75M	-1.48M	860K	7.37M	111K	-7.43M	-949.55K	-2.11M
Cash from Investing+	-21.19M	24.47M	-18.58M	5.35M	5.16M	-35.65M	-8.14M	8.3M	3.99K	-9K
Capital Expenditures	-1.63M	-120K	-1.18M	-58K	-203K	-53.77M	-115K	-198K	-10.97K	-9K
CapEx % of Revenue	544.67%	1.19%	0.29%	0.01%	0.03%	0.84%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-17.94M	36.87M	-11.96M	-35K	-35K	0	-8.03M	0	0	0
Cash from Financing+	54.79M	36.02M	25.65M	41.76M	35.51M	84.37M	73.46M	11.45M	21.38M	8.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	108K	263K	3.44M	-139K	5K	-15.95M	-3.39M	-10.88M	8.64M	790K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.46M	-28.38M	-45.95M	-34.52M	-40.95M	-102.35M	-65.16M	-29.38M	-35.83M	-9.38M
FCF Margin %	-6486.67%	-280.97%	-11.47%	-4.13%	-6.51%	-1.59%	-0.76%	-0.48%	-5.49%	-1.17%
FCF Growth %	-0.46%	-0.46%	-0.62%	0.25%	-0.19%	-1.5%	0.36%	0.55%	-0.22%	0.74%
FCF per Share	-871.01	-1101.63	-1301.18	-746.54	-689.61	-1404.91	-700.26	-237.23	-69.14	-3.81
FCF Conversion (FCF/Net Income)	0.85x	0.96x	0.98x	0.89x	0.96x	0.64x	0.67x	0.41x	-1.50x	1.13x
Interest Paid	0	0	0	0	0	0	0	0	0	55K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-49.57%	-47.84%	-84.52%	-80.66%	-76.09%	-206.25%	-859.7%	-	1155.91%	-
Return on Invested Capital (ROIC)	-57.22%	-96.5%	-207.75%	-116.16%	-113.74%	-89.89%	-87.75%	-52.88%	36.44%	-
Gross Margin	-733300%	-30140.59%	46.94%	66.06%	64.09%	42.68%	42.39%	46.06%	47.03%	60.31%
Net Margin	-703000%	-29079.21%	-1136.61%	-464.35%	-672.45%	-118.36%	-113.98%	-115.97%	366.25%	-102.8%
Debt / Equity	-	-	-	-	0.06x	6.27x	9.89x	-	0.57x	-
Interest Coverage	-1833.50x	-4363.29x	-674.96x	-235.51x	-98.31x	-5.12x	-4.90x	-1.04x	34.42x	-265.69x
FCF Conversion	0.85x	0.96x	0.98x	0.89x	0.96x	0.64x	0.67x	0.41x	-1.50x	1.13x
Revenue Growth	-99.96%	3266.67%	3867.33%	108.63%	-24.75%	923.03%	33.25%	-27.94%	-89.43%	23.17%

Revenue by Segment

	2024
Movantik	900K
Movantik Growth	-

Frequently Asked Questions

Growth & Financials

RedHill Biopharma Ltd. (RDHL) reported $9.5M in revenue for fiscal year 2024. This represents a 41422% increase from $0.0M in 2011.

RedHill Biopharma Ltd. (RDHL) grew revenue by 23.2% over the past year. This is strong growth.

RedHill Biopharma Ltd. (RDHL) reported a net loss of $9.3M for fiscal year 2024.

Dividend & Returns

RedHill Biopharma Ltd. (RDHL) had negative free cash flow of $8.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

RedHill Biopharma Ltd. (RDHL) 10-Year Financial Performance & Capital Metrics

RDHL • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsGastrointestinal Therapeutics

Revenue $8M +23.2%
EBITDA -$14M -195.7%
Net Income -$8M -134.6%
EPS (Diluted) -7.00 -115.2%
Gross Margin 60.31% +28.2%
EBITDA Margin -173.99% -177.7%
Operating Margin -181.69% -193.9%
Net Margin -102.8% -128.1%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -265.69 -871.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 1155.9%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.38%

5Y5.04%

3Y-54.57%

TTM157.62%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM69.14%

EPS CAGR

10Y-

5Y-

3Y-

TTM90.7%

ROCE

10Y Avg-33.82%

5Y Avg9.65%

3Y Avg95.91%

Latest-

Peer Comparison

Gastrointestinal Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRWDIronwood Pharmaceuticals, Inc.	735.31M	4.52	821.82	-20.63%	8.42%		14.06%
TAKTakeda Pharmaceutical Company Limited	51.59B	16.33	0.49	7.45%	0.75%	0.46%	100%	0.73
RDHLRedHill Biopharma Ltd.	6.67M	1.31	-0.19	23.17%	-97.52%
EVOKEvoke Pharma, Inc.	18.95M	11.00	-3.91	97.84%	-36.23%	-155.44%		0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3K	101K	4.01M	8.36M	6.29M	64.36M	85.76M	61.8M	6.53M	8.04M
Revenue Growth %	-1%	32.67%	38.67%	1.09%	-0.25%	9.23%	0.33%	-0.28%	-0.89%	0.23%
Cost of Goods Sold+	22M	30.54M	2.13M	2.84M	2.26M	36.89M	49.41M	33.34M	3.46M	3.19M
COGS % of Revenue	7334%	302.41%	0.53%	0.34%	0.36%	0.57%	0.58%	0.54%	0.53%	0.4%
Gross Profit+	-22M	-30.44M	1.88M	5.52M	4.03M	27.47M	36.35M	28.46M	3.07M	4.85M
Gross Margin %	-7333%	-301.41%	0.47%	0.66%	0.64%	0.43%	0.42%	0.46%	0.47%	0.6%
Gross Profit Growth %	-4.69%	-0.38%	1.06%	1.94%	-0.27%	5.81%	0.32%	-0.22%	-0.89%	0.58%
Operating Expenses+	22M	30.64M	53.85M	44.85M	47.23M	91.15M	117.49M	71.31M	-9.56M	19.46M
OpEx % of Revenue	7335%	303.41%	13.44%	5.37%	7.51%	1.42%	1.37%	1.15%	-1.46%	2.42%
Selling, General & Admin	4.13M	5.4M	20.04M	19.99M	29.81M	74.66M	87.99M	64.03M	30.98M	15.52M
SG&A % of Revenue	1378%	53.5%	5%	2.39%	4.74%	1.16%	1.03%	1.04%	4.74%	1.93%
Research & Development	17.77M	25.24M	32.97M	24.86M	17.42M	16.49M	29.5M	7.28M	3.53M	1.59M
R&D % of Revenue	5923.67%	249.91%	8.23%	2.97%	2.77%	0.26%	0.34%	0.12%	0.54%	0.2%
Other Operating Expenses	100K	0	845K	0	0	0	0	0	-44.06M	2.36M
Operating Income+	-22M	-30.54M	-51.97M	-39.33M	-43.2M	-63.68M	-81.14M	-42.84M	12.63M	-14.61M
Operating Margin %	-7334%	-302.41%	-12.97%	-4.7%	-6.87%	-0.99%	-0.95%	-0.69%	1.93%	-1.82%
Operating Income Growth %	-1.07%	-0.39%	-0.7%	0.24%	-0.1%	-0.47%	-0.27%	0.47%	1.29%	-2.16%
EBITDA+	-21.97M	-30.5M	-51.89M	-39.24M	-41.99M	-54.94M	-62.99M	-34.69M	14.62M	-13.99M
EBITDA Margin %	-7322%	-301.97%	-12.95%	-4.69%	-6.67%	-0.85%	-0.73%	-0.56%	2.24%	-1.74%
EBITDA Growth %	-1.07%	-0.39%	-0.7%	0.24%	-0.07%	-0.31%	-0.15%	0.45%	1.42%	-1.96%
D&A (Non-Cash Add-back)	36K	44K	81K	90K	1.21M	8.74M	18.15M	8.15M	1.99M	619K
EBIT	-22M	-30.54M	-45.54M	-38.82M	-41.91M	-63.72M	-81.18M	-30.34M	24.28M	-8.21M
Net Interest Income+	224K	275K	220K	237K	5.02K	-12.27M	-16.58M	-41.19M	-273K	78K
Interest Income	236K	282K	6.5M	678K	444.43K	176K	51K	140K	94K	133K
Interest Expense	12K	7K	77K	167K	439.42K	12.45M	16.57M	41.33M	367K	55K
Other Income/Expense	812K	1.17M	6.43M	511K	897K	-12.49M	-16.61M	-28.82M	11.28M	6.34M
Pretax Income+	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Pretax Margin %	-7030%	-290.79%	-11.37%	-4.64%	-6.72%	-1.18%	-1.14%	-1.16%	3.66%	-1.03%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Net Margin %	-7030%	-290.79%	-11.37%	-4.64%	-6.72%	-1.18%	-1.14%	-1.16%	3.66%	-1.03%
Net Income Growth %	-0.97%	-0.39%	-0.55%	0.15%	-0.09%	-0.8%	-0.28%	0.27%	1.33%	-1.35%
Net Income (Continuing)	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-950.00	-1100.00	-1300.00	-850.00	-700.00	-1000.00	-1000.00	-600.00	46.00	-7.00
EPS Growth %	-0.58%	-0.16%	-0.18%	0.35%	0.18%	-0.43%	0%	0.4%	1.08%	-1.15%
EPS (Basic)	-950.00	-1100.00	-1300.00	-850.00	-700.00	-1000.00	-1000.00	-600.00	46.00	-7.00
Diluted Shares Outstanding	22.34K	25.76K	35.31K	46.24K	59.38K	72.85K	93.05K	123.86K	518.24K	2.46M
Basic Shares Outstanding	22.16K	25.7K	35.31K	46.24K	59.38K	72.85K	93.05K	123.86K	518.24K	2.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60.51M	67.81M	51.68M	56.79M	53.21M	70.5M	89.15M	85.9M	16.14M	11.91M
Cash & Short-Term Investments	58.14M	66.15M	46.2M	53.19M	47.87M	29.79M	38M	19.98M	6.36M	4.62M
Cash Only	21.52M	53.79M	16.45M	29M	29.02M	29.3M	29.47M	19.97M	5.57M	4.62M
Short-Term Investments	36.62M	12.37M	29.75M	24.18M	18.85M	498K	8.53M	15K	790.04K	0
Accounts Receivable	220K	492K	2.26M	1.4M	1.64M	29.29M	32.52M	37.88M	3.29M	3.57M
Days Sales Outstanding	26.77K	1.78K	206.05	60.91	94.86	166.11	138.43	223.7	183.62	161.83
Inventory	-34.47M	1.11M	653K	769K	1.88M	6.53M	14.81M	11.01M	4.39M	3.65M
Days Inventory Outstanding	-	13.31	112.11	98.94	304.09	64.57	109.41	120.54	463.14	417.49
Other Current Assets	0	0	0	0	0	0	0	16M	797.04K	0
Total Non-Current Assets+	6.32M	6.4M	5.67M	5.62M	20.89M	109.75M	92.04M	72.97M	6.91M	6.13M
Property, Plant & Equipment	124K	165K	230K	163K	3.81M	5.7M	4.22M	7.19M	1.18M	437K
Fixed Asset Turnover	0.02x	0.61x	17.42x	51.29x	1.65x	11.29x	20.31x	8.59x	5.52x	18.41x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	6.06M	6.09M	5.29M	5.32M	16.93M	87.88M	71.64M	65.63M	5.58M	5.55M
Long-Term Investments	134K	137K	152K	140K	152K	0	16.17M	150K	147K	148K
Other Non-Current Assets	134K	137K	152K	-5.62M	-20.73M	32.33M	16.17M	150K	41	0
Total Assets+	66.83M	74.21M	57.34M	62.41M	74.1M	180.24M	181.19M	158.87M	23.05M	18.04M
Asset Turnover	0.00x	0.00x	0.07x	0.13x	0.08x	0.36x	0.47x	0.39x	0.28x	0.45x
Asset Growth %	1.32%	0.11%	-0.23%	0.09%	0.19%	1.43%	0.01%	-0.12%	-0.85%	-0.22%
Total Current Liabilities+	5.51M	5.36M	11.83M	10.38M	10.62M	73.23M	81.47M	197.45M	19.24M	22.22M
Accounts Payable	119K	60K	4.8M	3.32M	4.18M	11.55M	11.66M	4.23M	3.28M	7.86M
Days Payables Outstanding	1.97	0.72	824.94	427.66	676.03	114.3	86.17	46.31	345.9	898.89
Short-Term Debt	0	0	0	0	0	1.71M	1.62M	115.22M	718K	353K
Deferred Revenue (Current)	0	0	0	0	1000K	1000K	1000K	0	0	0
Other Current Liabilities	325K	393K	1.06M	1.46M	-2.89M	-1.71M	12.03M	49.65M	10.76M	10.96M
Current Ratio	10.97x	12.66x	4.37x	5.47x	5.01x	0.96x	1.09x	0.44x	0.84x	0.54x
Quick Ratio	17.23x	12.45x	4.31x	5.40x	4.84x	0.87x	0.91x	0.38x	0.61x	0.37x
Cash Conversion Cycle	-	1.79K	-506.78	-267.81	-277.09	116.37	161.67	297.92	300.85	-319.58
Total Non-Current Liabilities+	1.24M	6.16M	448K	844K	3.48M	93.14M	90.84M	9.82M	1.74M	503K
Long-Term Debt	0	0	0	0	0	81.39M	83.62M	0	0	0
Capital Lease Obligations	0	0	0	0	2.98M	3.81M	2.57M	6.44M	455K	3K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.24M	6.16M	448K	844K	500K	7.95M	4.65M	3.37M	540K	500K
Total Liabilities	6.75M	11.51M	12.28M	11.22M	14.1M	166.38M	172.31M	207.27M	20.98M	22.73M
Total Debt+	0	0	0	0	3.81M	86.9M	87.81M	122.69M	1.17M	356K
Net Debt	-21.52M	-53.79M	-16.45M	-29M	-25.21M	57.61M	58.34M	102.72M	-4.4M	-4.26M
Debt / Equity	-	-	-	-	0.06x	6.27x	9.89x	-	0.57x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	0.08x	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-0.30x	-
Interest Coverage	-1833.50x	-4363.29x	-674.96x	-235.51x	-98.31x	-5.12x	-4.90x	-1.04x	34.42x	-265.69x
Total Equity+	60.08M	62.7M	45.06M	51.19M	60M	13.86M	8.88M	-48.4M	2.07M	-4.68M
Equity Growth %	1.4%	0.04%	-0.28%	0.14%	0.17%	-0.77%	-0.36%	-6.45%	1.04%	-3.26%
Book Value per Share	2688.97	2434.05	1276.12	1106.96	1010.41	190.30	95.37	-390.77	3.99	-1.90
Total Shareholders' Equity	60.08M	62.7M	45.06M	51.19M	60M	13.86M	8.88M	-48.4M	2.07M	-4.68M
Common Stock	343K	441K	575K	767K	962K	1.05M	1.5M	2.83M	21.44M	35.04M
Retained Earnings	-61.94M	-89.64M	-132.94M	-169.09M	-208.36M	-280.33M	-367.87M	-433.86M	-407.74M	-414.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-126K	-170K	-251K	-341K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.83M	-28.26M	-44.77M	-34.46M	-40.75M	-48.58M	-65.05M	-29.18M	-35.82M	-9.37M
Operating CF Margin %	-5942%	-279.78%	-11.17%	-4.12%	-6.48%	-0.75%	-0.76%	-0.47%	-5.49%	-1.16%
Operating CF Growth %	-0.46%	-0.59%	-0.58%	0.23%	-0.18%	-0.19%	-0.34%	0.55%	-0.23%	0.74%
Net Income	-21.09M	-29.37M	-45.54M	-38.82M	-42.3M	-76.17M	-97.74M	-71.67M	23.92M	-8.27M
Depreciation & Amortization	36K	44K	81K	90K	1.21M	8.74M	18.15M	8.15M	1.99M	619K
Stock-Based Compensation	1.36M	1.68M	2.23M	2.68M	3.03M	4.2M	10.21M	5.67M	1.65M	665K
Deferred Taxes	-638K	-1.26M	-5.08M	136K	0	195K	123K	0	0	0
Other Non-Cash Items	-69K	94K	-123K	35K	-347K	6.03M	5.37M	20.65M	-47.79M	-4.44M
Working Capital Changes	2.57M	553K	3.66M	1.42M	-2.34M	8.42M	-1.15M	8.01M	-15.58M	2.05M
Change in Receivables	701.73K	713.24K	-1.43M	570K	-258K	-27.44M	-3.02M	-2.85M	33.43M	52K
Change in Inventory	0	0	-653K	-116K	-1.11M	-4.64M	-8.29M	3.8M	2.38M	738K
Change in Payables	1.87M	-158K	4.75M	-1.48M	860K	7.37M	111K	-7.43M	-949.55K	-2.11M
Cash from Investing+	-21.19M	24.47M	-18.58M	5.35M	5.16M	-35.65M	-8.14M	8.3M	3.99K	-9K
Capital Expenditures	-1.63M	-120K	-1.18M	-58K	-203K	-53.77M	-115K	-198K	-10.97K	-9K
CapEx % of Revenue	544.67%	1.19%	0.29%	0.01%	0.03%	0.84%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-17.94M	36.87M	-11.96M	-35K	-35K	0	-8.03M	0	0	0
Cash from Financing+	54.79M	36.02M	25.65M	41.76M	35.51M	84.37M	73.46M	11.45M	21.38M	8.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	108K	263K	3.44M	-139K	5K	-15.95M	-3.39M	-10.88M	8.64M	790K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.46M	-28.38M	-45.95M	-34.52M	-40.95M	-102.35M	-65.16M	-29.38M	-35.83M	-9.38M
FCF Margin %	-6486.67%	-280.97%	-11.47%	-4.13%	-6.51%	-1.59%	-0.76%	-0.48%	-5.49%	-1.17%
FCF Growth %	-0.46%	-0.46%	-0.62%	0.25%	-0.19%	-1.5%	0.36%	0.55%	-0.22%	0.74%
FCF per Share	-871.01	-1101.63	-1301.18	-746.54	-689.61	-1404.91	-700.26	-237.23	-69.14	-3.81
FCF Conversion (FCF/Net Income)	0.85x	0.96x	0.98x	0.89x	0.96x	0.64x	0.67x	0.41x	-1.50x	1.13x
Interest Paid	0	0	0	0	0	0	0	0	0	55K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-49.57%	-47.84%	-84.52%	-80.66%	-76.09%	-206.25%	-859.7%	-	1155.91%	-
Return on Invested Capital (ROIC)	-57.22%	-96.5%	-207.75%	-116.16%	-113.74%	-89.89%	-87.75%	-52.88%	36.44%	-
Gross Margin	-733300%	-30140.59%	46.94%	66.06%	64.09%	42.68%	42.39%	46.06%	47.03%	60.31%
Net Margin	-703000%	-29079.21%	-1136.61%	-464.35%	-672.45%	-118.36%	-113.98%	-115.97%	366.25%	-102.8%
Debt / Equity	-	-	-	-	0.06x	6.27x	9.89x	-	0.57x	-
Interest Coverage	-1833.50x	-4363.29x	-674.96x	-235.51x	-98.31x	-5.12x	-4.90x	-1.04x	34.42x	-265.69x
FCF Conversion	0.85x	0.96x	0.98x	0.89x	0.96x	0.64x	0.67x	0.41x	-1.50x	1.13x
Revenue Growth	-99.96%	3266.67%	3867.33%	108.63%	-24.75%	923.03%	33.25%	-27.94%	-89.43%	23.17%

Revenue by Segment

	2024
Movantik	900K
Movantik Growth	-

Frequently Asked Questions

Growth & Financials

RedHill Biopharma Ltd. (RDHL) reported $9.5M in revenue for fiscal year 2024. This represents a 41422% increase from $0.0M in 2011.

RedHill Biopharma Ltd. (RDHL) grew revenue by 23.2% over the past year. This is strong growth.

RedHill Biopharma Ltd. (RDHL) reported a net loss of $9.3M for fiscal year 2024.

Dividend & Returns

RedHill Biopharma Ltd. (RDHL) had negative free cash flow of $8.2M in fiscal year 2024, likely due to heavy capital investments.